| Document |
Document Title |
|
WO/2004/084842A2 |
The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., ca...
|
|
WO/2004/078144A2 |
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering...
|
|
WO/2004/076401A1 |
The invention relates to arlylcycloalkyl-substituted alkanoic acid derivatives and the physiologically acceptable salts and physiologically functional derivatives thereof. Disclosed are compounds of formula (I), wherein the radicals have...
|
|
WO/2004/077511A2 |
The present invention provides novel (meth)acrylic and (meth)acrylamide monomers and polymers produced from those monomers. The monomers of the invention each include only a single vinyl functionality and at least one non-vinyl functiona...
|
|
WO/2004/076432A1 |
The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain.
|
|
WO/2004/073709A1 |
Compounds of formula (I) are antibacterial agents: wherein B represents R2R3N-, R2NH-C(=NR3)-, or R2NH-C(=NR3)-NR4- wherein each of R2, R3 and R4 represents hydrogen or a C1-C6 alkyl, phenyl, phenyl(C1-C6 alkyl)-, monocyclic heteroaryl, ...
|
|
WO/2004/072020A1 |
This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present inventi...
|
|
WO/2004/069823A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2004/067499A1 |
A fluorinated urethane compound represented by the general formula I[-NHC(=O)O-((Rf-A1-)X1O)a-R1]m[-NHC(=O)O-((ClCH2-)X2O)b-R2]
n (1) (wherein I is a group formed by removing isocyanate groups from a polyisocyanate compound; Rf is C3-21 ...
|
|
WO/2004/067522A1 |
Novel azaphenylalanine derivatives of the formula I and pharmaceutically acceptable salts thereof are described wherein the substituents have the meanings as specified in the description. The compounds are useful as anticoagulants.
|
|
WO/2004/067500A1 |
O-Isopropylisourea hydrogen sulfate and O-isopropyl- isourea sulfate which are represented by the general formula (I); and a process for the production thereof: (I) [wherein X is HSO4 or 1/2SO4]. O-Isopropylisourea hydrogen sulfate can b...
|
|
WO/2004/065356A1 |
The invention relates to compounds of formula (I) wherein the radicals have the cited meaning, in addition to the physiologically compatible salts thereof. The compounds, for example, can be used as medicaments for preventing and treatin...
|
|
WO/2004/064730A2 |
Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
|
|
WO/2004/065351A1 |
Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention imp...
|
|
WO/2004/063181A1 |
The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comp...
|
|
WO/2004/063147A1 |
The invention provides salts and solvated of glucagon antagonists.
|
|
WO/2004/062601A2 |
Antibacterial compounds of formula (I) are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
WO/2004/058747A1 |
The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention ...
|
|
WO/2004/058683A2 |
Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds having structure (I), including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein X, ...
|
|
WO/2004/058164A2 |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...
|
|
WO/2004/058686A1 |
The present invention relates to compounds of formula (I); useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the betasecretase enzyme that are useful in the treatment of Alzheimer'...
|
|
WO/2004/058145A2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
WO/2004/058690A1 |
The invention relates to agents for dyeing keratin fibres, especially human hair, said agents containing at least one p-phenylenediamine derivative of formula (I) in a cosmetically acceptable medium, as a developing constituent. In said ...
|
|
WO/2004/056763A2 |
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
|
|
WO/2004/052838A1 |
The present invention describes compounds of general formula (I), a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutical agents. The compounds according ...
|
|
WO/2004/052845A1 |
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...
|
|
WO/2004/052846A1 |
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/052840A1 |
The invention relates to novel compounds that correspond to the general formula (I) below and to a method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatolog...
|
|
WO/2004/050609A1 |
The invention provides compounds of formula I: useful in treating Alzheimer’s disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer’s disease...
|
|
WO/2004/048319A1 |
Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is furth...
|
|
WO/2004/046162A2 |
ABSTRACT Potent non-steroidal farnesoid X receptor (FXR) agonists are N-aryl-N-arylmethyl amido and ureido compounds having the chemical structure represented by the following formula (I): INSERT FORMULA wherein E1 is (C1-C8)alkyl, cyclo...
|
|
WO/2004/046091A2 |
The invention relates to novel biaromatic compounds which correspond to the general formula (I), and also to a process for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (i...
|
|
WO/2004/046090A2 |
This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are...
|
|
WO/2004/043899A1 |
The invention concerns 4-aminomethyl-1-aryl-cyclohexylamine derivatives, methods for producing same, medicines containing said compounds and the use of 4-aminomethyl-1-aryl-cyclohexylamine derivatives for producing medicines.
|
|
WO/2004/043909A1 |
The invention relates to cyclohexylurea derivatives, methods for the production thereof, medicaments containing said compounds, and the use of cyclohexylurea derivatives for producing medicaments.
|
|
WO/2004/041211A2 |
One aspect of the present invention relates to urea-containing compounds. In certain embodiments, the urea-containing compounds of the present invention comprise a heteroaromatic moiety. Another aspect of the present invention relates to...
|
|
WO/2004/039865A1 |
The invention relates to a process wherein one or more polyamines, each with one or more -NH2 functions and one or more second amine functions, said second amine functions having a lower lactone reactivity than said -NH2 functions, is re...
|
|
WO/2004/039764A1 |
The invention relates to amide compounds of general formula (I), in which the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. The invention further relates to medicaments comprising at least one...
|
|
WO/2004/039766A1 |
The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of...
|
|
WO/2004/039762A1 |
The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of...
|
|
WO/2004/037777A1 |
The invention features tetralin and indane compounds of Formula I, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.
|
|
WO/2004/037778A1 |
The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, dyslipidemia.
|
|
WO/2004/035533A1 |
The present invention relates to novel n-hydroxythiourea, urea and amide compounds as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to ...
|
|
WO/2004/033416A2 |
The invention concerns carboxyalkoxy-substituted acyl-carboxyphenyl-urea derivatives of formula (I) wherein the groups are such as defined in the description and their physiologically acceptable salts and their physiologically functional...
|
|
WO/2004/033422A2 |
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted ...
|
|
WO/2004/028538A1 |
Small organic molecules capable of effecting a 'pharmacological trabeculocanalotomy' in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity ...
|
|
WO2003051276B1 |
Compounds of formula (I) or (II) wherein R1 , R2 , R3 , R4 , W, Q, G, X and Y are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are usefu...
|
|
WO2003027064B1 |
The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions comprising such analogues, and their uses as vanilloid receptor agonistsand potent analgesics.The present ...
|
|
WO/2004/026815A2 |
The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -...
|
